Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» IPF
IPF
Boehringer Ingelheim's Ofev nabs FDA nod for expanded use in rare lung disease
Fierce Pharma
Mon, 03/9/20 - 11:19 pm
Boehringer Ingelheim
IPF
Ofev
FDA
ILD
With one rival down, Novartis-partnered biotech scores $100M round to fund mid-stage trials of fibrosis drug
Endpoints
Tue, 03/3/20 - 11:02 am
Pliant Therapeutics
IPF
Biogen
Novartis
Biogen stops Phase 2 study in another hit to 'high-risk' pipeline
Biopharma Dive
Tue, 09/17/19 - 03:38 pm
Biogen
clinical trials
IPF
idiopathic pulmonary fibrosis
BG00011
Looking for Ofev follow-up, Boehringer picks up Bridge Biotherapeutics' IPF med for $50M
Fierce Biotech
Thu, 07/18/19 - 11:38 am
Boehringer Ingelheim
Bridge Biotherapeutics
Ofeva
IPF
BBT-877
Looking to resolve lingering doubts, Gilead unleashes a $5B late-stage cash alliance with Galapagos
Endpoints
Sun, 07/14/19 - 04:01 pm
Gilead Sciences
Galapagos
IPF
osteoarthritis
Roivant launches lung-focused Respivant with phase 2 IPF drug
Fierce Biotech
Tue, 09/18/18 - 10:12 am
Roivant
Respivant Sciences
IPF
RVT-1601
Chasing Biogen, the Pliant crew banks a $62M round to fuel their shot at fibrosis targets
Endpoints
Mon, 07/16/18 - 09:57 am
Pliant Therapeutics
IPF
idiopathic pulmonary fibrosis
Latest Phase 2 Data Shows Pamrevlumab Reduces Rate of Progression in Idiopathic Pulmonary Fibrosis
CP Wire
Tue, 05/22/18 - 11:11 am
FibroGen
pamrevlumab
IPF
idiopathic pulmonary fibrosis
Sanofi ditches IL-4/IL-13 antibody drug in lung-scarring disease
Fierce Biotech
Thu, 11/2/17 - 09:25 am
Sanofi
IL-4/IL-13 antibodies
SAR156597
IPF
Galapagos spotlights an ‘exciting’ round of PoC data for IPF drug, shares surge
Endpoints
Thu, 08/10/17 - 11:53 am
Galapagos
IPF
GLPG1690
FibroGen
EC clears Boehringer Ingelheim's Ofev for idiopathic pulmonary fibrosis
First Word Pharma
Mon, 01/19/15 - 12:02 pm
Boehringer Ingelheim
Ofev
IPF
idiopathic pulmonary fibrosis
Europe
Bristol-Myers beefs up fibrosis pipeline with $444M option deal
Fierce Biotech
Mon, 11/3/14 - 09:28 am
Bristol-Myers Squibb
Galecto Biotech
Denmark
M&A
IPF
idiopathic pulmonary fibrosis
Boehringer revs up Ofev sales force, support services to rival Roche's Esbriet in IPF
Fierce Pharma Marketing
Thu, 10/23/14 - 08:41 am
Boehringer Ingelheim
drug reps
Ofev
Roche
Esbriet
IPF
Roche, Boehringer Drugs Wins Approval for Lung Disease
Bloomberg
Wed, 10/15/14 - 04:49 pm
Roche
Boehringer Ingelheim
FDA
IPF
idiopathic pulmonary fibros
Esbriet
Ofev
The 3 Biggest Biotech Wins of the Week
Motley Fool
Wed, 05/28/14 - 10:52 am
GS-5806
Gilead Sciences
Factor XI inhibitor
Isis Pharmaceuticals
InterMune
pirfenidone
IPF
InterMune Gains After Lung Disease Drug Slows Damage
Bloomberg
Mon, 05/19/14 - 09:36 am
InterMune
pirfenidone
IPF
idiopathic pulmonary fibrosis
Biotech Stock Mailbag: Previewing InterMune's Big Week Ahead
TheStreet.com
Fri, 05/16/14 - 10:07 am
InterMune
IPF
idiopathic pulmonary fibrosis
Boehringer Ingelheim
pirfenidone
nintedanib
InterMune Hits Home Run With Pivotal Lung Drug Study Results
TheStreet.com
Tue, 02/25/14 - 08:14 am
InterMune
pirfenidone
IPF
idiopathic pulmonary fibrosis
Rejection of InterMune’s Drug Told Early to FDA Advisers
Bloomberg
Wed, 12/26/12 - 09:23 am
FDA
InterMune
Esbriet
IPF
InterMune Gearing Up For Another Round With The FDA
Yahoo/Reuters
Thu, 11/29/12 - 12:03 pm
InterMune
FDA
IPF
idiopathic pulmonary fibrosis
pirfenidone
Pages
« first
‹ previous
1
2
3
next ›
last »